Oct 28 2009
Adamas Pharmaceuticals, an emerging pharmaceutical company focused on developing small-molecule therapeutics to treat neurological and infectious diseases, selected Veeva System’s VBioPharma™ KOL Edition – part of the Veeva CRM suite. Selection of Veeva’s SaaS solution marks an important step in Adamas’ early-stage product commercialization strategy. Veeva CRM is currently being rolled out to Adamas’ customer facing teams in sales and marketing and clinical management, and will scale with the company as it grows.
Adamas initially considered making the heavy investment in a custom-built system that would support the company’s unique needs until being recommended to Veeva CRM for its specialized KOL functionality, low cost, and ease of customization. Veeva demonstrated the product…and Adamas was immediately convinced. Executives cited the product’s flexibility – both in terms of licensing and system configuration; its scalability; and, its world-class performance from economies of scale only possible with multi-tenant SaaS applications.
“We researched the market and even considered a home-grown alternative, but no other system delivered the specific KOL functionality that we needed plus the outstanding flexibility and scalability of a large-scale enterprise system,” said Michael Cheung, director of information technology at Adamas. “In fact, the product has proven so deeply flexible that we have been able to customize it for our clinical trial management team as well. One system with a huge data repository and multiple tools for all of our needs and everyone to use…this is the way all companies should operate.”
According to Veeva’s Executive Vice President and General Manager, Matt Wallach, “We’re proud to be a part of Adamas’ exciting entry into the industry because we have the right infrastructure to help this company launch its product and expand quickly. Our multi-tenant SaaS architecture truly levels the playing field for emerging life sciences leaders like Adamas because they benefit from the advantages of world-class technology they might not otherwise be able to afford.”